×
About 80,200 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  37,279 results

A synergetic effect of BARD1 mutations on tumorigenesis.
https://doi.org/10.1038/s41467-021-21519-3 10.1016/j.molcel.2010.09.019 10.1038/35044005 10.1038/nature08467 10.1038/nature03482 10.1038/nature10760 10.1038/nrm2831 10.1016/j.ccr.2013.03.025 10.1126/science.7545954 10.1001/jama.2017.7112 10.1371/journal.pgen.1003212 10.1146/annurev.genet.32.1.95 10.1126/science.1088759 10.1038/ng1296-430 10.1038/nsb1001-833 10.1073/pnas.211427098 10.1074/jbc.274.9.5659 10.1074/jbc.M200769200 10.1101/gad.1381306 10.1074/jbc.M413741200 10.1016/S0092-8674(00)80503-6 10.1074/jbc.C000881200 10.1016/S0959-437X(01)00269-6 10.1038/nsmb.3236 10.1038/nature24060 10.1038/nrc1878 10.1128/MCB.23.14.5056-5063.2003 10.1038/nrclinonc.2016.90 10.1111/cge.12620 10.1001/jamaoncol.2015.5495 10.1038/nrc.2016.72 10.1038/nmeth0410-248 10.1101/gr.176601 10.1093/bioinformatics/btv195 10.1093/nar/gkq929 10.1038/s41568-018-0060-1 10.1086/303029 10.1093/hmg/ddi476 10.1093/emboj/cdf691 10.1073/pnas.1715467115 10.1038/ng837 10.1038/nsmb.2078 10.1101/gad.226357.113 10.1126/science.aaa4055 10.1038/s41422-018-0009-7 10.1016/S0092-8674(01)00301-4 10.1021/ja804289g 10.1073/pnas.0711032105 10.1126/science.1139516 10.1038/sj.onc.1207302 10.1038/sj.onc.1207427 10.1126/science.1235122 10.1038/nature17676 10.1038/nature24284 10.1371/journal.pmed.0030217 10.1002/gcc.1223 10.1136/jmg.2004.020669 10.1007/s10549-007-9799-x 10.1007/s10549-008-0045-y 10.1158/1055-9965.EPI-10-0909 10.1093/bioinformatics/btp324 10.1093/bioinformatics/btp352 10.1101/gr.107524.110 10.1093/nar/gkq603 10.1038/nsb1001-833 10.1002/cpbi.3 10.1002/prot.21123 10.1126/science.265.5176.1219 10.1063/1.448118 10.1021/ct700301q 10.1080/00268978300102851 10.1063/1.464397 10.1002/jcc.20291 10.1038/nprot.2006.5 10.1186/1471-2105-10-80
Nature Communications; Li W, Gu X et. al.

Feb 24th, 2021 - To date, a large number of mutations have been screened from breast and ovarian cancer patients. However, most of them are classified into benign or unidentified alterations due to their undetectable phenotypes. Whether and how they could cause tu...

Depot-medroxyprogesterone acetate use is associated with decreased risk of ovarian canc...
https://doi.org/10.1158/1055-9965.EPI-20-1355
Cancer Epidemiology, Biomarkers & Prevention : a Publicat... Phung MT, Lee AW et. al.

Feb 23rd, 2021 - Background Combined oral contraceptive use is associated with a decreased risk of invasive epithelial ovarian cancer (ovarian cancer). There is suggestive evidence of an inverse association between progestin-only contraceptive use and ovarian canc...

Comprehensive mutational analysis of the BRCA1-associated DNA helicase and tumor suppre...
https://doi.org/10.1158/1541-7786.MCR-20-0828
Molecular Cancer Research : MCR; Calvo JA, Fritchman B et. al.

Feb 23rd, 2021 - FANCJ (BRIP1/BACH1) is a hereditary breast and ovarian cancer (HBOC) gene encoding a DNA helicase. Similar to HBOC genes, BRCA1 and BRCA2, FANCJ is critical for processing DNA inter-strand crosslinks (ICL) induced by chemotherapeutics, such as cis...

"From chemo to chemo"-the temporal paradox of chemotherapy.
https://doi.org/10.1007/s00520-021-06039-6 10.1111/j.1471-6712.2012.01019.x 10.12968/ijpn.2008.14.10.31490 10.1080/13698575.2013.830081 10.1016/j.ejon.2019.02.002 10.1111/j.1365-2648.2006.04133.x 10.5172/conu.2012.41.2.146 10.1111/j.1745-7599.2012.00732.x 10.1016/j.tjog.2019.11.032 10.1188/19.CJON.E100-E106 10.4135/9781526405555.n11 10.1163/156916212X632934
Supportive Care in Cancer : Official Journal of the Multi... Moskalewicz M, Popova Y et. al.

Feb 23rd, 2021 - To uncover the experience of time in women undergoing chemotherapy for ovarian cancer. A combination of consensual qualitative research and Giorgi's descriptive phenomenology. The key phenomenon found and pre-reflectively organizing the patients' ...

The role of altered long noncoding RNAs in overall survival of ovarian cancer: A system...
https://doi.org/10.1016/j.prp.2021.153363
Pathology, Research and Practice; Seyed Hosseini E, Alizadeh Zarei M et. al.

Feb 23rd, 2021 - In recent years, tremendous research efforts have been focused on investigating the effect of dysregulation of lncRNAs on cancer progression, most of which confirm a positive link. This inspired us to conduct the present meta-analysis to explore w...

see more →

Guidelines  225 results

ESMO recommendations on predictive biomarker testing for homologous recombination defic...
https://doi.org/10.1016/j.annonc.2020.08.2102
Annals of Oncology : Official Journal of the European Soc... Miller RE, Leary A et. al.

Oct 2nd, 2020 - Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an oppor...

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival wi...

Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: Internatio...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294297
Gynecologic Oncology; Elledge CR, Beriwal S et. al.

Jun 21st, 2020 - To develop expert consensus recommendations regarding radiation therapy for gynecologic malignancies during the COVID-19 pandemic. An international committee of ten experts in gynecologic radiation oncology convened to provide consensus recommenda...

see more →

Drugs  133 results see all →

Clinicaltrials.gov  40,071 results

A synergetic effect of BARD1 mutations on tumorigenesis.
https://doi.org/10.1038/s41467-021-21519-3 10.1016/j.molcel.2010.09.019 10.1038/35044005 10.1038/nature08467 10.1038/nature03482 10.1038/nature10760 10.1038/nrm2831 10.1016/j.ccr.2013.03.025 10.1126/science.7545954 10.1001/jama.2017.7112 10.1371/journal.pgen.1003212 10.1146/annurev.genet.32.1.95 10.1126/science.1088759 10.1038/ng1296-430 10.1038/nsb1001-833 10.1073/pnas.211427098 10.1074/jbc.274.9.5659 10.1074/jbc.M200769200 10.1101/gad.1381306 10.1074/jbc.M413741200 10.1016/S0092-8674(00)80503-6 10.1074/jbc.C000881200 10.1016/S0959-437X(01)00269-6 10.1038/nsmb.3236 10.1038/nature24060 10.1038/nrc1878 10.1128/MCB.23.14.5056-5063.2003 10.1038/nrclinonc.2016.90 10.1111/cge.12620 10.1001/jamaoncol.2015.5495 10.1038/nrc.2016.72 10.1038/nmeth0410-248 10.1101/gr.176601 10.1093/bioinformatics/btv195 10.1093/nar/gkq929 10.1038/s41568-018-0060-1 10.1086/303029 10.1093/hmg/ddi476 10.1093/emboj/cdf691 10.1073/pnas.1715467115 10.1038/ng837 10.1038/nsmb.2078 10.1101/gad.226357.113 10.1126/science.aaa4055 10.1038/s41422-018-0009-7 10.1016/S0092-8674(01)00301-4 10.1021/ja804289g 10.1073/pnas.0711032105 10.1126/science.1139516 10.1038/sj.onc.1207302 10.1038/sj.onc.1207427 10.1126/science.1235122 10.1038/nature17676 10.1038/nature24284 10.1371/journal.pmed.0030217 10.1002/gcc.1223 10.1136/jmg.2004.020669 10.1007/s10549-007-9799-x 10.1007/s10549-008-0045-y 10.1158/1055-9965.EPI-10-0909 10.1093/bioinformatics/btp324 10.1093/bioinformatics/btp352 10.1101/gr.107524.110 10.1093/nar/gkq603 10.1038/nsb1001-833 10.1002/cpbi.3 10.1002/prot.21123 10.1126/science.265.5176.1219 10.1063/1.448118 10.1021/ct700301q 10.1080/00268978300102851 10.1063/1.464397 10.1002/jcc.20291 10.1038/nprot.2006.5 10.1186/1471-2105-10-80
Nature Communications; Li W, Gu X et. al.

Feb 24th, 2021 - To date, a large number of mutations have been screened from breast and ovarian cancer patients. However, most of them are classified into benign or unidentified alterations due to their undetectable phenotypes. Whether and how they could cause tu...

Depot-medroxyprogesterone acetate use is associated with decreased risk of ovarian canc...
https://doi.org/10.1158/1055-9965.EPI-20-1355
Cancer Epidemiology, Biomarkers & Prevention : a Publicat... Phung MT, Lee AW et. al.

Feb 23rd, 2021 - Background Combined oral contraceptive use is associated with a decreased risk of invasive epithelial ovarian cancer (ovarian cancer). There is suggestive evidence of an inverse association between progestin-only contraceptive use and ovarian canc...

Comprehensive mutational analysis of the BRCA1-associated DNA helicase and tumor suppre...
https://doi.org/10.1158/1541-7786.MCR-20-0828
Molecular Cancer Research : MCR; Calvo JA, Fritchman B et. al.

Feb 23rd, 2021 - FANCJ (BRIP1/BACH1) is a hereditary breast and ovarian cancer (HBOC) gene encoding a DNA helicase. Similar to HBOC genes, BRCA1 and BRCA2, FANCJ is critical for processing DNA inter-strand crosslinks (ICL) induced by chemotherapeutics, such as cis...

"From chemo to chemo"-the temporal paradox of chemotherapy.
https://doi.org/10.1007/s00520-021-06039-6 10.1111/j.1471-6712.2012.01019.x 10.12968/ijpn.2008.14.10.31490 10.1080/13698575.2013.830081 10.1016/j.ejon.2019.02.002 10.1111/j.1365-2648.2006.04133.x 10.5172/conu.2012.41.2.146 10.1111/j.1745-7599.2012.00732.x 10.1016/j.tjog.2019.11.032 10.1188/19.CJON.E100-E106 10.4135/9781526405555.n11 10.1163/156916212X632934
Supportive Care in Cancer : Official Journal of the Multi... Moskalewicz M, Popova Y et. al.

Feb 23rd, 2021 - To uncover the experience of time in women undergoing chemotherapy for ovarian cancer. A combination of consensual qualitative research and Giorgi's descriptive phenomenology. The key phenomenon found and pre-reflectively organizing the patients' ...

The role of altered long noncoding RNAs in overall survival of ovarian cancer: A system...
https://doi.org/10.1016/j.prp.2021.153363
Pathology, Research and Practice; Seyed Hosseini E, Alizadeh Zarei M et. al.

Feb 23rd, 2021 - In recent years, tremendous research efforts have been focused on investigating the effect of dysregulation of lncRNAs on cancer progression, most of which confirm a positive link. This inspired us to conduct the present meta-analysis to explore w...

see more →

News  2,425 results

Study: Pap Test/Cervical Swab Samples Can Reveal Ovarian Cancer Biomarkers
https://www.medscape.com/viewarticle/946396

Feb 23rd, 2021 - Residual fixatives from liquid-based Pap tests and cervical swabs contain tumor-specific biomarkers for ovarian cancer, according to an analysis of proteins found in matched biospecimens from a woman with high grade serous ovarian cancer. The find...

London Team Identifies New Prognostic Biomarker for Ovarian Cancer
https://www.medscape.com/viewarticle/924968

Jan 31st, 2021 - A team of surgeons from Imperial College London have discovered a new biomarker for poor prognosis in patients with advanced high-grade serous ovarian cancer (HGSOC). In research published in the  British Journal of Cancer,  the team identified an...

Nulliparity, Not ART, Likely Raises Risk of Ovarian Cancer
https://www.medscape.com/viewarticle/944346

Jan 18th, 2021 - Women who receive ovarian stimulation for assisted reproductive technology (ART) procedures don't have an increased risk of developing ovarian cancer when compared to subfertile women who don't undergo ART, according to a new study. The results su...

NICE Approves 'Game-changing' Ovarian Cancer Drug
https://www.medscape.com/viewarticle/944178

Jan 14th, 2021 - Niraparib (Zejula, GlaxoSmithKline) has been approved by the National Institute for Health and Care Excellence (NICE) for England's Cancer Drugs Fund (CDF) for some women with advanced ovarian cancer. The decision means the drug should also be ava...

Radiotherapy for Rectal Cancer Linked to Risk for Later Malignant Gynecological Neoplasms
https://www.medscape.com/viewarticle/943852

Jan 10th, 2021 - (Reuters Health) - Women who receive radiotherapy for rectal cancer may be at an increased risk of uterine and ovarian cancer, a new study suggests. In an analysis of information from the SEER database on more than 20,000 female patients diagnosed...

see more →

Patient Education  67 results see all →